December 1, 2020
SAN RAMON, Calif. – The CooperVision MiSight 1 day contact lens has been awarded a 2020 Popular Science “Best of What’s New Award” in the health category. The daily wear, single-use contact lens is the first and only FDA-approved* product to slow the progression of myopia when initially prescribed for children 8-12 years old,1 and it is the cornerstone of CooperVision’s Brilliant Futures Myopia Management Program.
The Popular Science “Best of What’s New Awards” recognize up to 100 of the most innovative technologies from the past year across 10 categories, such as health, home, aerospace, and security. Each product or technology must represent a significant step forward in its category.
“The Best of What’s New Awards showcase the year’s greatest feats of human ingenuity,” said Popular Science Editor-in-Chief Corinne Iozzio. “Even in a year like 2020, innovation has helped us glimpse a future that’s safer, smarter, and more enjoyable than we might have thought possible.”
More than 2,000 U.S. eye care professionals (ECPs) are now certified and able to prescribe CooperVision’s Brilliant Futures Myopia Management Program. The widespread reach and prominence of the Popular Science “Best of What’s New Awards” will likely drive even more parents to seek information about participating ECPs.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
[1] Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-67.
